| [1] Klingenberg M. Pigments of rat liver microsomes. Archs Biochem Biophys, 1958, 75:376-386.
[2] Pedersen R S, Damkier P, Christensen M M, et al. A cytochrome P450 phenotyping cocktail causing unexpected adverse reactions in female volunteers. Eur J Clin Pharmacol, 2013,69(12):1997-1999.
[3] Venkatakrishnan K, Von M L, Greenblatt D J. Human drug metabolism and the cytochromes P450:application and relevance of in vitro models. J Clin Pharmacol, 2001, 41(11):1149-1179.
[4] Donzelli M, Derungs A, Serratore M G, et al. The basel cocktail for simultaneous phenotyping of human cytochrome P450 isoforms in plasma, saliva and dried blood spots. Clin Pharmacokinet, 2014,53(3):271-282.
[5] Kirchheiner J, Nickchen K, Bauer M, et al. Pharmacogenetics of antidepressants and antipsychotics:the contribution of allelic variations to the phenotype of drug response. Mol Psychiatry, 2004,9:442-473.
[6] Danielson P B.The cytochrome P450 superfamily:biochemistry, evolution and drug metabolism in humans. Current Drug Metabolism, 2002, 3(6):561-597.
[7] David Ra. Comparison of cytochrome P450(CYP) genes from the mouse and human genomes, including nomenclature recommendations for genes, pseudogenes and alternative-splice variants. Pharmacogenetics, 2004,14:1-18.
[8] Ma C, Adjei A, Salavaggione O, et al. Human aromatase (CYP19) pharmacogenomics:Gene resequencing and functional genomics. Clinical Pharmacology & Therapeutics, 2005, 77(2):22.
[9] Zanger U, Turpeinen M, Klein K, et al. Functional pharmacogenetics/genomics of human cytocromes P450 involved in drug biotransformation. Anal Bioanal Chem,2008, 392,1093-1108.
[10] Bradford L D. CYP2D6 allele frequency in European caucasians, Asians, Africans, and their descendants. Pharmacogenomics, 2002,3:229-243.
[11] Satomi Y, Nishino H. Inhibition of the enzyme activity of cytochrome P4501A1, 1A2 and 3A4 by fucoxanthin, a marine carotenoid. Oncol Lett, 2013,6(3):860-864.
[12] Yoshinari K, Ntoriyabe Y. Constitutive androstane receptor transcriptionally activates human CYP1A1 and CYP1A2 genes through a common regulatory element in the 5'-flanking region. Biochemical Pharmacology, 2010,79(2):261-269.
[13] Sansen S, Yano J K, Reynald R L, et al. Adaptations for the oxidation of polycyclic aromatic hydrocarbons exhibited by the structure of human P4501A2. Journal of Biological Chemistry, 2007, 282(19):14348-14355.
[14] Gunes A, Dahl M L. Variation in CYP1A2 activity and its clinical implications:influence of environmental factors and genetic polymorphisms. Pharmacogenomics, 2008, 9(5):625-637..
[15] Shao W, He J. CYP1A2 rs2069514 polymorphism and lung cancer susceptibility:a meta-analysis. Annals of Translational Medicine, 2015, 3(7):93.
[16] Allorge D, Chevalier D, Lo-Guidice J M, et al. Identification of a novel splice-site mutation in the CYP1A2 gene. Br J Clin Pharmacol, 2003,56:341-344.
[17] Linder M W, Looney S, Iii J E, et al. Warfarin dose adjustments based on CYP2C9 genetic polymorphisms. Journal of Thrombosis and Thrombolysis, 2002, 14(3):227-232.
[18] Allabi A C, Gala J L, Horsmans Y, et al. Functional impact of CYP2C9*5, CYP2C9*6, CYP2C9*8, and CYP2C9*11 in vivo among black Africans. Clin Pharmacol Ther, 2004, 76:113-118.
[19] Si D, Guo Y, Zhang Y, et al.Identification of a novel variant CYP2C9 allele in Chinese. Pharmacogenetics, 2004, 14:465-469.
[20] Dai D P, Li C B, Wang S H, et al. Identification and characterization of a novel CYP2C9 allelic variant in a warfarin-sensitive patient. Pharmacogenomics, 2015,16(13):1475-1486.
[21] Lee S J, Kim W Y, Kim H, et al. Identification of new CYP2C19 variants exhibiting decreased enzyme activity in the metabolism of S-mephenytoin and omeprazole. Drug Metab Dispos, 2009, 37(11):2262-2269.
[22] Klotz U. Clinical impact of CYP2C19 polymorphism on the action of proton pump inhibitors:a review of a special problem. Int J Clin Pharmacol Ther, 2006, 44(7):297-302.
[23] Sim S C, Risinger C, Dahl M L, et al. A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants. Clin Pharmacol Ther, 2006, 79:103-113.
[24] Chaudhry A S, Prasad B, Shirasaka Y, et al. The CYP2C19 intron 2 branch point SNP is the ancestral polymorphism contributing to the poor metabolizer phenotype in livers with CYP2C19*35 and CYP2C19*2 alleles. Drug Metab Dispos, 2015, 43(8):1226-1335.
[25] Sheng H H,Zeng A P,Zhu W X,et al.Allelic distributions of CYP2D6 gene copy number variation in the eastern Han Chinese population. Acta Phamacol Sin, 2007, 28:279-286.
[26] Shen H, He M M, Liu H, et al. Comparative metabolic capabilities and inhibitory profiles of CYP2D6.1, CYP2D6.10, and CYP2D6.17. Drug Metab Dispos,2007, 35:1292-1300.
[27] Borba M A, Meloneto R P, Leitão G M, et al. Evaluating the impact of missenses mutations in CYP2D6*7 and CYP2D6*14A:does it compromise tamoxifen metabolism.Pharmacogenomics, 2016, 17(6):573-582.
[28] Lamba J K, Lin Y S, Schuetz E G, et al. Genetic contribution to variable human CYP3A-mediated metabolism. Adv Drug Deliv Rev, 2002, 54:1271-1294.
[29] Du J, Yu L,Wang L, et al. Differences in CYP3A4*1G genotype distribution and haplotypes of CYP3A4, CYP3A5 and CYP3A7 in 3 Chinese populations. Clin Chim Acta, 2007, 383(4):172-174.
[30] Hsieh K P, Lin Y Y, Cheng C L, et al. Novel mutations of CYP3A4 in Chinese. Drug Metab Dispos, 2001, 29:268-273.
[31] Dai D, Tang J, Rose R, et al. Identification of variants of CYP3A4 and characterization of their abilities to metabolize testosterone and chlorpyrifos. J Pharmacol Exp Ther, 2001,299:825-831.
[32] Werk A N, Lefeldt S, Bruckmueller H, et al. Identification and characterization of a defective CYP3A4 genotype in a kidney transplant patient with severely diminished tacrolimus clearance. Clin Pharmacol Ther, 2014, 95(4):416-422.
[33] Wang X D, Li J L. A pharmacogenetic study of pregnane X receptor (NR1I2) in Han Chinese. Curr Drug Metab, 2007, 8:778-786. |
